These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30928643)

  • 21. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
    Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
    Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification.
    Meng Y; Sohar I; Wang L; Sleat DE; Lobel P
    PLoS One; 2012; 7(7):e40509. PubMed ID: 22792360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
    Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE
    PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis.
    Wang YL; Zeng ZY; Song XW; Hao ZF; Shi YW; Tang B; Chen SQ; Gao MM; Di W; Long YS; Yi YH; Liao WP
    Neurogenetics; 2011 Feb; 12(1):93-5. PubMed ID: 20820830
    [No Abstract]   [Full Text] [Related]  

  • 26. Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.
    Domowicz MS; Chan WC; Claudio-Vázquez P; Henry JG; Ware CB; Andrade J; Dawson G; Schwartz NB
    ASN Neuro; 2019; 11():1759091419843393. PubMed ID: 31003587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.
    Munesue Y; Ageyama N; Kimura N; Takahashi I; Nakayama S; Okabayashi S; Katakai Y; Koie H; Yagami KI; Ishii K; Tamaoka A; Yasutomi Y; Shimozawa N
    Exp Neurol; 2023 May; 363():114381. PubMed ID: 36918063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
    Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
    Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses.
    Chang X; Huang Y; Meng H; Jiang Y; Wu Y; Xiong H; Wang S; Qin J
    Brain Dev; 2012 Oct; 34(9):739-45. PubMed ID: 22245569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
    Phillips JE; Gomer RH
    Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes.
    Haney MJ; Zhao Y; Jin YS; Batrakova EV
    Cells; 2020 May; 9(5):. PubMed ID: 32443895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis.
    Sanders DN; Kanazono S; Wininger FA; Whiting RE; Flournoy CA; Coates JR; Castaner LJ; O'Brien DP; Katz ML
    Genes Brain Behav; 2011 Oct; 10(7):798-804. PubMed ID: 21745338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.
    Chen ZR; Liu DT; Meng H; Liu L; Bian WJ; Liu XR; Zhu WW; He Y; Wang J; Tang B; Su T; Yi YH
    Seizure; 2019 Jul; 69():180-185. PubMed ID: 31059981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene symbol: TPP1. Disease: Neuronal Ceroid Lipofuscinosis, late infantile.
    Kohan R; Muller VJ; Fietz MJ; Cismondi AI; Oller Ramírez AM; Halac IN
    Hum Genet; 2008 Jun; 123(5):553. PubMed ID: 20960655
    [No Abstract]   [Full Text] [Related]  

  • 35. CLN2 disease resulting from a novel homozygous deep intronic splice variant in TPP1 discovered using long-read sequencing.
    Steigerwald C; Borsuk J; Pappas J; Galey M; Scott A; Devaney JM; Miller DE; Abreu NJ
    Mol Genet Metab; 2023 Dec; 140(4):107713. PubMed ID: 37922835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease.
    El-Hage N; Haney MJ; Zhao Y; Rodriguez M; Wu Z; Liu M; Swain CJ; Yuan H; Batrakova EV
    Cells; 2023 May; 12(11):. PubMed ID: 37296618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies.
    Geraets RD; Langin LM; Cain JT; Parker CM; Beraldi R; Kovacs AD; Weimer JM; Pearce DA
    PLoS One; 2017; 12(5):e0176526. PubMed ID: 28464005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerliponase alfa decreases Aβ load and alters autophagy- related pathways in mouse hippocampal neurons exposed to fAβ
    Kose S; Cinar E; Akyel H; Cakir-Aktas C; Tel BC; Karatas H; Kelicen-Ugur P
    Life Sci; 2024 Nov; 357():123105. PubMed ID: 39362589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients.
    Kohan R; Cismondi IA; Kremer RD; Muller VJ; Guelbert N; Anzolini VT; Fietz MJ; Ramírez AM; Halac IN
    Clin Genet; 2009 Oct; 76(4):372-82. PubMed ID: 19793312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful PGD for late infantile neuronal ceroid lipofuscinosis achieved by combined chromosome and TPP1 gene analysis.
    Shen J; Cram DS; Wu W; Cai L; Yang X; Sun X; Cui Y; Liu J
    Reprod Biomed Online; 2013 Aug; 27(2):176-83. PubMed ID: 23768618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.